273 related articles for article (PubMed ID: 9184402)
21. Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion.
Metz DC; Devlin JW; Vakily M; Atkinson S; Lloyd E
Pharmacotherapy; 2008 Mar; 28(3):301-7. PubMed ID: 18294109
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
Bichler J; Siebeck M; Fichtl B; Fritz H
Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
[TBL] [Abstract][Full Text] [Related]
23. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
Rübsamen K; Hornberger W
Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
[TBL] [Abstract][Full Text] [Related]
24. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.
Tripodi A; Chantarangkul V; Arbini AA; Moia M; Mannucci PM
Thromb Haemost; 1993 Aug; 70(2):286-8. PubMed ID: 8236136
[TBL] [Abstract][Full Text] [Related]
25. The pharmacology of recombinant hirudin, a new anticoagulant.
Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
[TBL] [Abstract][Full Text] [Related]
26. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
Rübsamen K; Kirchengast M
Coron Artery Dis; 1998; 9(1):35-42. PubMed ID: 9589189
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
28. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion.
Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F
Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533
[TBL] [Abstract][Full Text] [Related]
29. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J
Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group.
Schiele F; Lindgaerde F; Eriksson H; Bassand JP; Wallmark A; Hansson PO; Grollier G; Sjo M; Moia M; Camez A; Smyth V; Walker M
Thromb Haemost; 1997 May; 77(5):834-8. PubMed ID: 9184388
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and partial thromboplastin time after intravenous recombinant hirudin variant-2 in rhesus monkeys.
Liu XW; Song HF; Tang ZM; Zhao K; Zhu BZ; Wang LP; Zhang Y
Acta Pharmacol Sin; 2002 Sep; 23(9):842-6. PubMed ID: 12230955
[TBL] [Abstract][Full Text] [Related]
36. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
38. Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteers.
Amin DM; Mant TG; Walker SM; Kerry R; Lloyd P; Lefèvre G; Close P
Thromb Haemost; 1997 Jan; 77(1):127-32. PubMed ID: 9031462
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of recombinant hirudin in healthy horses.
Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
[TBL] [Abstract][Full Text] [Related]
40. UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis.
O'Brien SH; Yee DL; Lira J; Goldenberg NA; Young G
J Thromb Haemost; 2015 Sep; 13(9):1615-22. PubMed ID: 26180006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
